Lotiglipron is a GLP-1 receptor agonist that was tested against semaglutide, the active ingredient of Novo Nordisk’s Ozempic and Wegovy. Among the study participants who experienced elevated liver enzymes, none saw related side effects, “there was no evidence of liver failure and none needed treatment,” Pfizer said in a news release.
Transaminitis is not a disease but can be a clue other issues — such as alcohol-related and non-alcohol-related fatty liver disease — exist.
The company said it will continue researching danuglipron, another GLP-1 receptor agonist that is in a phase 2 study for obesity and Type 2 diabetes mellitus. No transaminase events have been reported in this drug’s trials, the release said.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
